+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 65Years
All Genders
ID07794475

Evaluating Trimetazidine Tablets Twice Daily for Treatment of Diabetic Peripheral Neuropathy and Its Effect on Endothelin-1 Levels

Led by Sara Refaat Azab Metry · Updated on 2026-08-31

60

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether trimetazidine can improve symptoms and clinical outcomes in patients with diabetic peripheral neuropathy, a complication of diabetes that affects nerve function. The study also aims to understand how trimetazidine influences endothelin-1 levels, a substance in the body potentially involved in this condition. This trial is an interventional study with a randomized, parallel design focused on treatment outcomes. Participants assigned to the treatment group will take trimetazidine tablets at a dose of 35 mg twice daily for three months. Another group will not receive this medication, serving as a control for comparison. The study involves no masking, meaning both researchers and participants know the treatment assignments. During the study, participants will be assessed at the start and after 12 weeks to measure endothelin-1 levels, neuropathic pain using the DN4 score, severity of diabetic neuropathy through the Toronto clinical scoring system, and pain intensity with a numeric rating scale. Side effects will be monitored every four weeks and at the end of the study. The total participation period spans three months, ensuring close follow-up and safety monitoring.

CONDITIONS

Brief Title

Effect of Trimetazidine on Endothelin-1 and Clinical Outcomes of Patients With Diabetic Peripheral Neuropathy

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here